Insider Trading Alert - UGI, NBS And MACK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 4, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $555.68 to $8,275,700.00.

Highlighted Stocks Traded by Insiders:

UGI (UGI) - FREE Research Report

Greenberg Lon R, who is Director at UGI, sold 45,628 shares at $37.51 on Dec. 4, 2014. Following this transaction, the Director owned 496,207 shares meaning that the stake was reduced by 8.42% with the 45,628-share transaction.

The shares most recently traded at $38.47, up $0.96, or 2.51% since the insider transaction. Historical insider transactions for UGI go as follows:

  • 4-Week # shares bought: 3,175
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 3,175
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 3,175
  • 24-Week # shares sold: 40,000

The average volume for UGI has been 1.1 million shares per day over the past 30 days. UGI has a market cap of $6.5 billion and is part of the utilities sector and utilities industry. Shares are up 37.48% year-to-date as of the close of trading on Wednesday.

UGI Corporation, through its subsidiaries, distributes, stores, transports, and markets energy products and related services in the United States and internationally. The stock currently has a dividend yield of 2.32%. The company has a P/E ratio of 19.6. Currently, there is 1 analyst who rates UGI a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UGI - FREE

TheStreet Quant Ratings rates UGI as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and revenue growth. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full UGI Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Neostem (NBS) - FREE Research Report

RimAsia Capital Partners Manager, Ltd., who is Director at Neostem, sold 12,000 shares at $4.01 on Dec. 4, 2014. Following this transaction, the Director owned 2.2 million shares meaning that the stake was reduced by 0.53% with the 12,000-share transaction.

The shares most recently traded at $3.82, down $0.19, or 5.08% since the insider transaction. Historical insider transactions for Neostem go as follows:

  • 4-Week # shares bought: 22,500
  • 4-Week # shares sold: 12,218
  • 12-Week # shares bought: 22,500
  • 12-Week # shares sold: 12,218
  • 24-Week # shares bought: 22,500
  • 24-Week # shares sold: 12,218

The average volume for Neostem has been 396,600 shares per day over the past 30 days. Neostem has a market cap of $141.9 million and is part of the health care sector and drugs industry. Shares are down 42.38% year-to-date as of the close of trading on Wednesday.

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. Currently, there are 5 analysts who rate Neostem a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBS - FREE

TheStreet Quant Ratings rates Neostem as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Neostem Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 8,000 shares at $8.71 on Dec. 4, 2014. Following this transaction, the Director owned 633,164 shares meaning that the stake was boosted by 1.28% with the 8,000-share transaction.

The shares most recently traded at $9.58, up $0.87, or 9.08% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 56,909
  • 12-Week # shares bought: 56,909
  • 24-Week # shares bought: 89,299

The average volume for Merrimack Pharmaceuticals has been 2.3 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $987.9 million and is part of the health care sector and drugs industry. Shares are up 75.01% year-to-date as of the close of trading on Wednesday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 3 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

What Do Trade Wars Mean for High Yield Bond Investors?

What Do Trade Wars Mean for High Yield Bond Investors?

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know